Published in Immunity on August 01, 1996
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72
Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med (2000) 2.40
Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol (2004) 2.12
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A (1998) 1.72
The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J (2000) 1.62
Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med (2000) 1.59
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med (2001) 1.50
Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A (1997) 1.38
The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci (2011) 1.35
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev (2010) 1.28
The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med (1998) 1.22
Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection. J Virol (2005) 1.15
A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. Biophys J (2000) 1.12
Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice. Proc Natl Acad Sci U S A (1998) 1.10
An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol (1998) 1.09
Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J Virol (2000) 1.05
Virus-induced diabetes in a transgenic model: role of cross-reacting viruses and quantitation of effector T cells needed to cause disease. J Virol (2000) 1.04
Precise identification of a human immunodeficiency virus type 1 antigen processing mutant. J Virol (2006) 1.02
Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J Exp Med (2000) 1.01
Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J Exp Med (1998) 0.98
Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals. J Immunol (2012) 0.98
Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci U S A (1997) 0.95
Bioinformatic analysis of functional differences between the immunoproteasome and the constitutive proteasome. Immunogenetics (2003) 0.93
A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J Exp Med (2000) 0.92
CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope. PLoS Pathog (2011) 0.87
Naturally occurring TAP-dependent specific T-cell tolerance for a variant of an immunodominant retroviral cytotoxic T-lymphocyte epitope. J Virol (2000) 0.82
Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol (2016) 0.81
Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood (2016) 0.77
Computational prediction of cleavage using proteasomal in vitro digestion and MHC I ligand data. J Zhejiang Univ Sci B (2013) 0.76
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol (2016) 0.76
The T210M Substitution in the HLA-a*02:01 gp100 Epitope Strongly Affects Overall Proteasomal Cleavage Site Usage and Antigen Processing. J Biol Chem (2015) 0.75
Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell (1984) 5.56
The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors. Curr Biol (2001) 3.64
Target cell-dependent T cell-mediated lysis of vaccinia virus-infected cells. Eur J Immunol (1975) 3.37
Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J (1984) 3.28
Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med (2000) 3.26
Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell (1991) 2.99
Lysis mediated by T cells and restricted by H-2 antigen of target cells infected with vaccinia virus. Nature (1975) 2.89
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79
The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature (2000) 2.70
Analysis and expression of a cloned pre-T cell receptor gene. Science (1994) 2.66
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
Mice lacking the MHC class II-associated invariant chain. Cell (1993) 2.30
The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I) Science (1996) 2.29
Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med (1992) 2.29
The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol (1999) 2.22
Dynamics of proteasome distribution in living cells. EMBO J (1997) 2.18
Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci U S A (1999) 2.17
Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med (1994) 2.13
Subcellular distribution of proteasomes implicates a major location of protein degradation in the nuclear envelope-ER network in yeast. EMBO J (1998) 2.06
Multivesicular body morphogenesis requires phosphatidyl-inositol 3-kinase activity. Curr Biol (1999) 2.00
Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature (1991) 1.97
High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA). Biotechniques (1999) 1.80
Benefits and risks of needle-knife papillotomy. Gastrointest Endosc (1997) 1.80
Direct vesicular transport of MHC class II molecules from lysosomal structures to the cell surface. J Cell Biol (1996) 1.80
Drosophila small cytoplasmic 19S ribonucleoprotein is homologous to the rat multicatalytic proteinase. Nature (1988) 1.80
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature (1992) 1.76
Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol (1994) 1.71
The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J Biol Chem (1995) 1.70
Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol (2001) 1.66
Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today (1996) 1.65
The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci U S A (1997) 1.64
Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene (2008) 1.59
Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med (2000) 1.59
20 S proteasomes are assembled via distinct precursor complexes. Processing of LMP2 and LMP7 proproteins takes place in 13-16 S preproteasome complexes. J Mol Biol (1994) 1.58
Preferential positive selection of V alpha 2+ CD8+ T cells in mouse strains expressing both H-2k and T cell receptor V alpha a haplotypes: determination with a V alpha 2-specific monoclonal antibody. Eur J Immunol (1992) 1.58
HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr Biol (1997) 1.57
Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med (2000) 1.54
Fusion of Sendai virus with the target cell membrane is required for T cell cytotoxicity. Nature (1978) 1.53
Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis. EMBO J (1996) 1.53
Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J Immunol (2000) 1.52
Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol (2000) 1.52
The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol (1997) 1.51
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med (2001) 1.50
The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem (2001) 1.46
Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol (2000) 1.44
Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J Immunol (2001) 1.44
Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity (2000) 1.41
Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur J Immunol (1995) 1.40
Impact of skill and experience of the endoscopist on the outcome of endoscopic sphincterotomy techniques. Gastrointest Endosc (1999) 1.37
MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J Immunol (2000) 1.37
TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol (1997) 1.36
Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med (1994) 1.36
A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol (1996) 1.35
The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci (2011) 1.35
Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J Immunol (1998) 1.34
Association between HLA-DM and HLA-DR in vivo. Immunity (1996) 1.34
A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. J Mol Biol (1999) 1.34
The Drosophila proteasome undergoes changes in its subunit pattern during development. Exp Cell Res (1989) 1.33
A ubiquitin-like protein which is synergistically inducible by interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol (1999) 1.28
Opposing motor activities of dynein and kinesin determine retention and transport of MHC class II-containing compartments. J Cell Sci (1999) 1.28
Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol (2001) 1.24
Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol (1994) 1.24
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res (2000) 1.24
Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol Cell (2001) 1.22
The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med (1998) 1.22
Developmental changes of the 26 S proteasome in abdominal intersegmental muscles of Manduca sexta during programmed cell death. J Biol Chem (1995) 1.20
Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol (1999) 1.20
The PROS-35 gene encodes the 35 kd protein subunit of Drosophila melanogaster proteasome. EMBO J (1989) 1.20
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol (2000) 1.20
Analysis of cytoplasmic 19 S ring-type particles in Drosophila which contain hsp 23 at normal growth temperature. Dev Biol (1985) 1.19
Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7(beta 5i) incorporation into 20 S proteasomes. J Mol Biol (2000) 1.19
Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP. Curr Biol (1996) 1.19
Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. J Immunol (1996) 1.19
The cleavage preference of the proteasome governs the yield of antigenic peptides. J Exp Med (1995) 1.19
Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol (1999) 1.19
Persistent infection of Epstein-Barr virus-positive B lymphocytes by human herpesvirus 8. J Virol (1998) 1.19
Cell-specific accumulation of Drosophila proteasomes (MCP) during early development. J Cell Biol (1990) 1.17
Major histocompatibility complex class II molecules induce the formation of endocytic MIIC-like structures. J Cell Biol (1994) 1.17
Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. J Immunol (1996) 1.16